Health ❯ Healthcare ❯ Biotechnology

Drug Development

Clinical Trials Oncology Inflammatory Diseases Gene Therapy Rare Diseases Obesity Treatments Obesity Treatment T-cell Engagers Inflammatory Bowel Disease Gilead Sciences Oral Therapeutics PROTACs Antimicrobials Neuromuscular Disorders Immunotherapy FDA Approval Cancer Research Regulatory Challenges Corcept Therapeutics Incorporated Clinical Research Hypertrophic Cardiomyopathy Immunology mRNA Vaccines Molecular Glue Degraders Multiple Myeloma Treatments Allergy Treatments Melanocortin 4 Receptor Therapies Cell Therapy Enzyme Replacement Therapy Mental Health Treatments Monoclonal Antibodies Therapeutics Orphan Drug Designation Telitacicept Petosemtamab Startup Support

Atara Investors Get May 22 Deadline to Seek Lead Role in Securities Suit

Plaintiffs say Atara hid FDA-flagged manufacturing issues plus ALLELE trial flaws.

FDA Grants Orphan Drug Status to Immutep’s Efti for Soft Tissue Sarcoma

SCYNEXIS Acquires Poxel’s PXL-770 for ADPKD, Plans 2026 Phase 2 Trial

FDA Grants Accelerated Approval to Avlayah for Neurologic Manifestations of Hunter Syndrome

Sanofi Licenses Kali’s Tri-Specific Autoimmune Antibody KT501 in Deal Worth Up to $1.23 Billion

Arvinas’ ARV-102 Hits >50% LRRK2 Degradation in Phase 1 Parkinson’s Trial

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

Jan. 16 Deadline Nears in Skye Bioscience Investor Class Actions

MoonLake Immunotherapeutics Investors Face Lead‑Plaintiff Deadline in Securities Fraud Suits

Skye Bioscience Investors Pressed to Seek Lead Role After Class Action Filing

Sofinnova Closes €650 Million Capital XI to Back Early-Stage Biotech and Medtech

MoonLake Investors Courted for Lead Role in SDNY Securities Case After SLK Trial Collapse

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline in SDNY Securities Case

MoonLake Faces Securities Class Action After SLK Trial Miss as Firms Seek Lead Plaintiff

Genmab to Buy Merus for $8 Billion to Secure Petosemtamab Cancer Drug

Kriya Nets $320 Million Series D as Odyssey Raises $213 Million and Amgen Retools Research Leadership

Frazier Life Sciences Closes $1.3 Billion Early-Stage Biotech Fund

FDA Flags Possible License Revocation for Sarepta’s Elevidys

AI-Designed Rentosertib Improves Lung Function in Phase IIa IPF Trial